Clinical trial
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare
NCT02749292 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- June 30, 2016
- Completion date
- January 31, 2022
- Enrollment
- 115 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.